TY - JOUR
T1 - Kidney failure related to broad-spectrum antibiotics in critically ill patients
T2 - secondary end point results from a 1200 patient randomised trial
AU - Jensen, Jens-Ulrik Stæhr
AU - Hein, Lars
AU - Lundgren, Bettina
AU - Bestle, Morten Heiberg
AU - Mohr, Thomas
AU - Andersen, Mads Holmen
AU - Thornberg, Klaus Julius
AU - Løken, Jesper
AU - Steensen, Morten
AU - Fox, Zoë
AU - Tousi, Hamid
AU - Søe-Jensen, Peter
AU - Lauritsen, Anne Øberg
AU - Strange, Ditte Gry
AU - Reiter, Nanna
AU - Thormar, Katrin
AU - Fjeldborg, Paul Christian
AU - Larsen, Kim Michael
AU - Drenck, Niels-Erik
AU - Johansen, Maria Egede
AU - Nielsen, Lene Ryom
AU - Kjær, Jesper
AU - Grarup, Jesper
AU - Lundgren, Jens D
AU - The Procalcitonin And Survival Study (PASS) Group
AU - Andersen, Christian Østergaard
PY - 2012
Y1 - 2012
N2 - OBJECTIVES: To explore whether a strategy of more intensive antibiotic therapy leads to emergence or prolongation of renal failure in intensive care patients. DESIGN: Secondary analysis from a randomised antibiotic strategy trial (the Procalcitonin And Survival Study). The randomised arms were conserved from the primary trial for the main analysis. SETTING: Nine mixed surgical/medical intensive care units across Denmark. PARTICIPANTS: 1200 adult intensive care patients, 18+ years, expected to stay +24 h. Exclusion criteria: bilirubin >40 mg/dl, triglycerides >1000 mg/dl, increased risk from blood sampling, pregnant/breast feeding and psychiatric patients. INTERVENTIONS: Patients were randomised to guideline-based therapy ('standard-exposure' arm) or to guideline-based therapy supplemented with antibiotic escalation whenever procalcitonin increased on daily measurements ('high-exposure' arm). MAIN OUTCOME MEASURES: Primary end point: estimated glomerular filtration rate (eGFR)
AB - OBJECTIVES: To explore whether a strategy of more intensive antibiotic therapy leads to emergence or prolongation of renal failure in intensive care patients. DESIGN: Secondary analysis from a randomised antibiotic strategy trial (the Procalcitonin And Survival Study). The randomised arms were conserved from the primary trial for the main analysis. SETTING: Nine mixed surgical/medical intensive care units across Denmark. PARTICIPANTS: 1200 adult intensive care patients, 18+ years, expected to stay +24 h. Exclusion criteria: bilirubin >40 mg/dl, triglycerides >1000 mg/dl, increased risk from blood sampling, pregnant/breast feeding and psychiatric patients. INTERVENTIONS: Patients were randomised to guideline-based therapy ('standard-exposure' arm) or to guideline-based therapy supplemented with antibiotic escalation whenever procalcitonin increased on daily measurements ('high-exposure' arm). MAIN OUTCOME MEASURES: Primary end point: estimated glomerular filtration rate (eGFR)
U2 - 10.1136/bmjopen-2011-000635
DO - 10.1136/bmjopen-2011-000635
M3 - Journal article
C2 - 22411933
SN - 2044-6055
VL - 2
SP - e000635
JO - BMJ Open
JF - BMJ Open
IS - 2
ER -